eMed
eMed runs telehealth and diagnostics, now pivoting to employer-sponsored GLP-1 weight loss programs.
On the record
Checkpoint: Results of eMed's capitated employer risk contracts and whether headcount stabilizes
The call
eMed sits between pharma giants building direct channels and AI tools that can run its own workflows, with no locked-in partnership of its own yet.
eMed connects patients to doctors for online prescriptions and manages the paperwork between them and pharmacies. Drug makers like Eli Lilly and Novo Nordisk are now selling directly to patients, insurance companies control which medicines get paid for, and artificial intelligence can handle the routine tasks (asking questions, checking if patients took their medicine, scheduling) that eMed employees currently do. The company has cut its staff in half over three years while its valuation went up, which is a warning sign: it looks like a company shrinking its way to nowhere, similar to what happened with the health app Babylon before it fell apart. The main thing to watch is whether drug companies make their direct-to-consumer operations so good that patients skip eMed entirely.
Why
01
AI pressure: General-purpose AI agents for triage, intake, and adherence check-ins. AI can already do eMed's core loop: test verification, symptom triage, medication nudges, without a human in the middle. Could AI do the core job? Yes, likely.
02
Bigger players: Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare) direct-to-consumer channels. Lilly and Novo now sell and ship GLP-1 drugs straight to patients, cutting into the intermediary role eMed depends on. Could a giant copy it? Yes, easily.
03
What protects it. An inherited NHS GP at Hand patient base and early employer GLP-1 contracts still bring in revenue while it rebuilds.
What would change this call
Whether eMed signs a binding exclusive pharma deal with Lilly or Novo Nordisk by end-2026. Would show eMed can secure the pharma access advantage Ro already has.
Whether eMed's headcount grows or keeps shrinking through end-2026. Would show whether the AI-native pivot is working or the business is contracting.
Whether NHS renews the inherited 'GP at Hand' contract from Babylon. Would show if eMed retains its main captive UK patient base or loses it.
Whether eMed's headcount grows or keeps shrinking through end-2026. Would show whether the AI-native pivot is working or the business is contracting.
Whether NHS renews the inherited 'GP at Hand' contract from Babylon. Would show if eMed retains its main captive UK patient base or loses it.
Key numbers
- $200M raised at over $2B valuation
- Headcount fell from 2,574 to 1,250 in 3 years
- LillyDirect DTC channel for Zepbound live since Dec 2024
Named risks
- Pharma manufacturers Lilly and Novo deepening direct-to-consumer GLP-1 channels, cutting out telehealth intermediaries.
- No independently verified outcome data behind eMed's adherence, weight loss and biomarker claims.
- Trajectory resembles Babylon Health, a $2B-valued telehealth firm that went bankrupt in 2023.
- PBMs and insurers already control formulary access, limiting eMed's pricing power.
- Core conversational workflows (triage, intake, adherence checks) are automatable by general AI agents.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Ro (Roman Health) | gaining on | Locked LillyDirect (Dec 2024) and NovoCare (Jan 2026) pharma deals eMed has not matched |
| Eli Lilly (LillyDirect) | losing to | Launched direct-to-consumer Zepbound channel bypassing telehealth intermediaries, Dec 2024 |
| Novo Nordisk (NovoCare) | losing to | Expanded direct Wegovy access including pill form, Jan 2026 |
| PBMs: Optum, CVS Caremark, Express Scripts | contesting | Control GLP-1 formulary access, can squeeze eMed's employer-program margins as of 2026 |
Questions people ask
- Is eMed profitable in 2026?
- eMed is private and discloses no revenue or profit figures. In March 2026 it raised $200M in a Series A led by Aon Consulting at a valuation of more than $2 billion, but that valuation reflects investor belief, not disclosed earnings.
- Could AI replace eMed's core telehealth services?
- Much of eMed's workflow (test verification, triage, intake, adherence check-ins) is exactly the kind of conversational task general AI agents can automate. eMed itself pivoted in March 2026 to brand itself an 'empathic agentic AI platform,' meaning it is racing to replace its own human-staffed processes.
- Who is eMed's biggest competitor?
- Ro (Roman Health) is eMed's closest and better-positioned rival, having locked pharma partnerships with Eli Lilly's LillyDirect (Zepbound, December 2024) and Novo Nordisk's NovoCare (Wegovy, January 2026), deals eMed has not matched as of July 2026.
- Who owns eMed?
- eMed is privately held. Its March 2026 round was led by Aon Consulting, with investors including Tom Brady (Founding Chief Wellness Officer), Joe Lonsdale, Jeff Aronin and Chicago Cubs chairman Tom Ricketts. Linda Yaccarino, former CEO of X, was named eMed CEO as of July 2026.
- Is eMed's UK NHS contract at risk?
- eMed Healthcare UK inherited the NHS 'GP at Hand' contract from Babylon Health's 2023 bankruptcy sale, along with roughly 700,000 patients and 1.2 million appointments (Aug 2022 to Aug 2023). The contract's renewal terms have not been publicly confirmed as of July 2026.
- Does eMed have independently verified health outcomes?
- No. eMed's reported figures, over 90% GLP-1 adherence, average 21 lb weight loss, and 99% biomarker improvement within six months, are all company-reported statistics from its own March 2026 PR, not audited by an independent third party.
Timeline
- 2026-07-12Linda Yaccarino, former X CEO, named eMed CEO
- 2026-03-26eMed raises $200M Series A at over $2B valuation, led by Aon Consulting
- 2026-03-26Tom Brady named Founding Chief Wellness Officer and investor
- 2026-01-01Novo Nordisk expands direct Wegovy access via NovoCare, including pill form
- 2024-12-01Eli Lilly launches LillyDirect direct-to-consumer channel for Zepbound
- 2023-10-19eMed Healthcare UK reports inheriting ~700k patients, 1.2M appointments from Babylon
- 2023-09-05eMed acquires bankrupt Babylon Health's UK assets, including GP at Hand contract
- 2023-08-31Babylon Health, once valued near $2B, goes bankrupt and sells for parts
- 2021-01-23eMed launches at-home COVID-19 rapid testing service
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- EMED RAISES $200 MILLION AT $2 BILLION PLUS VALUATION (2026-03-26)
- Linda Yaccarino named eMed CEO; telehealth startup valued at $2B (2026-07-12)
- Tom Brady-Backed eMed Raises $200M, Hits $2B Valuation (2026-03-26)
- Employee Count & Headcount Data (2026-06-29)
- Tom Brady-backed telehealth firm eMed valued at over $2 billion in latest funding round (2026-03-26)
- Ro (company)
- Babylon Health sells majority of UK assets to eMed (2023-09-05)
- eMed Healthcare UK promises continuity and expansion following successful acquisition of Babylon (2023-10-19)
- Tom Brady's eMed Health Startup Scores $2 Billion Valuation (2026-03-26)
- A GLP-1 Program Designed Around Ongoing Support (2026-07-18)
- Tom Brady-backed telehealth AI startup eMed raises $200M, tops $2B valuation (2026-03-30)
- Found Best Alternatives for Each Use Case (2026-05-26)